Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prelude Therapeutics Incorporated filings document the formal disclosures of a clinical-stage precision oncology company developing targeted cancer therapies. Recent 8-K reports cover Regulation FD materials, financial results, FDA and IND-related updates for PRT12396, preclinical data for PRT13722, and investor presentation materials.
The company’s SEC record also includes proxy disclosures on board matters, shareholder voting, executive compensation, and equity awards. Capital-structure filings describe Prelude’s Nasdaq-listed common stock, shelf registration and prospectus supplement activity, and at-the-market equity sales arrangements, while other material-event reports document leadership appointments and related employment and compensation arrangements.
Prelude Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026 at 8:30 a.m. Eastern. Proposals include electing three Class III directors through 2029, ratifying Ernst & Young LLP as auditor for 2026, approving executive pay on an advisory basis, and choosing how often to hold future advisory pay votes, with the Board recommending one year. The proxy describes Nasdaq-based governance practices, Board committee structure, anti-hedging and clawback policies, and director independence. It also details 2025 director and executive compensation, including stock option grants and incentive bonuses, and discloses ownership, with 48,299,663 shares of common stock entitled to vote as of April 16, 2026 and 64,914,770 voting common shares outstanding as of April 27, 2026.
Prelude Therapeutics Incorporated Schedule 13G: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report collective beneficial ownership totaling 6,477,309 shares, representing 9.99% of voting common stock under the Pre-Funded Warrants' ownership blocker. The filing explains voting and dispositive power delegations and ownership calculations based on outstanding share counts.
Prelude Therapeutics Inc disclosed that RA Capital Healthcare Fund, L.P., an entity associated with RA Capital Management, entered into an Exchange Agreement with the company. The Fund exchanged 1,407,000 shares of Common Stock for a Pre-Funded Warrant exercisable for up to 1,407,000 Common shares at an exercise price of $0.0001 per share, for no additional consideration.
The Pre-Funded Warrant is exercisable immediately, has no expiration date, and includes a 9.99% beneficial ownership cap that limits exercises if they would push the Fund and its attribution parties above that ownership level. Following the restructuring, the Fund indirectly held 6,475,882 shares of Common Stock and 1,407,000 Pre-Funded Warrants. RA Capital Management, its general partner, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership except to the extent of their respective pecuniary interests.
Prelude Therapeutics Inc received an initial ownership report from RA Capital–related entities. The filing shows 7,882,882 shares of Common Stock held indirectly and reported as held directly by RA Capital Healthcare Fund, L.P. The investment adviser, its general partner, and individuals Peter Kolchinsky and Rajeev Shah each disclaim beneficial ownership except to the extent of their pecuniary interests.
OrbiMed-affiliated funds filed Amendment No. 3 to their Schedule 13D on Prelude Therapeutics to update ownership after a recent underwritten offering.
Prelude sold 18,018,014 shares at $4.44 and pre-funded warrants for 2,252,252 shares at $4.4399, bringing total outstanding shares to 80,971,642. OrbiMed’s vehicles now beneficially own 12,935,071 shares of common stock, representing about 16% of the company. This includes 11,808,945 shares held by OrbiMed Private Investments VI and 1,126,126 shares held by OrbiMed Genesis Master Fund. Certain OrbiMed funds also hold non-voting shares that can only convert into voting shares if doing so would keep their ownership below a 9.99% blocker threshold.
Prelude Therapeutics Inc reported that investment entities affiliated with OrbiMed made indirect open-market purchases of its Common Stock in connection with an underwritten public offering. OrbiMed-related funds acquired blocks of 1,126,126 and 1,689,189 shares at $4.44 per share, with indirect holdings after one transaction reaching 11,808,945 shares. The securities are held of record by OrbiMed-managed funds, and OrbiMed Advisors exercises voting and investment power through a management committee. David P. Bonita, a director and ten percent owner, reports these positions but, together with the OrbiMed entities, disclaims beneficial ownership except to the extent of any pecuniary interest.
Prelude Therapeutics Inc reported that investment entities affiliated with OrbiMed made significant open-market purchases of its common stock. OrbiMed-related funds bought a combined 2,815,315 shares at $4.44 per share in an underwritten public offering, with all holdings reported as indirect and subject to detailed ownership footnotes.
The filing attributes shares to OrbiMed Private Investments VI, OrbiMed Partners Master Fund, and OrbiMed Genesis Master Fund through their respective general partners and advisors, while OrbiMed reporting entities and individual managers disclaim beneficial ownership beyond any pecuniary interest. One OrbiMed representative, David Bonita, serves on Prelude’s board.
Baker Bros. Advisors filed an amended Schedule 13D reporting beneficial ownership of 10,295,301 shares of Prelude Therapeutics common stock, representing 15.5% of the class. This reflects participation in an April 2026 offering of 18,018,014 common shares and prefunded warrants to purchase 2,252,252 shares at $4.4399 each, alongside a $4.44 common share price.
The filing explains that these prefunded warrants and separate non-voting common stock are subject to ownership caps of 4.99% and 9.99%, adjustable up to 19.99% with 61 days’ notice. It also describes option grants to Baker-affiliated directors, an omnibus option amendment tying exercisability to a current adviser representative, and a director lock-up running from April 20 to June 19, 2026.
Prelude Therapeutics Inc reported that investment funds advised by Baker Bros. Advisors LP made open-market purchases of prefunded warrants in an underwritten public offering. 667, L.P. acquired 114,601 prefunded warrants and Baker Brothers Life Sciences LP acquired 2,137,651 prefunded warrants, each at $4.4399 per warrant.
The prefunded warrants are exercisable into common stock on a 1-for-1 basis at an exercise price of $0.0001 per share, with no expiration date. Exercises are limited so that the holders and certain affiliates do not exceed 4.99% beneficial ownership, a cap the funds can adjust up to 19.99% with advance written notice. Baker Bros. Advisors LP has investment and voting discretion over the funds’ positions, while various Baker entities and Julian and Felix Baker disclaim beneficial ownership beyond their pecuniary interests.